University of California, Los Angeles, Radiation Oncology
Welcome,         Profile    Billing    Logout  
 7 Trials 
10 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lee, Percy
GUIDANCE, NCT05050084: Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score

Recruiting
3
2050
Canada, US
Bicalutamide, Casodex, Cosudex, ICI 176,334, ICI 176334, Buserelin, 6-[O-(1,1-Dimethylethyl)-D-serine]-9-(N-ethyl-L-prolinamide)-10-deglycinamide-luteinizing Hormone-releasing Factor (Pig), BSRL, Busereline, Etilamide, HOE 766, ICI 123215, S74-6766, Darolutamide, Antiandrogen ODM-201, BAY 1841788, BAY-1841788, BAY1841788, Nubeqa, ODM 201, ODM-201, Degarelix, FE200486, Firmagon, Flutamide, 4'-Nitro-3'-trifluoromethylisobutyranilide, Apimid, Cebatrol, Chimax, Cytomid, Drogenil, Euflex, Eulexine, Flucinom, Flucinome, Flugerel, Fluken, Flulem, FLUT, Fluta-Gry, Flutabene, Flutacan, Flutamex, Flutamin, Flutan, Flutaplex, Fugerel, Grisetin, Niftolide, Oncosal, Profamid, Propanamide, 2-Methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)-, Prostacur, Prostadirex, Prostica, Prostogenat, Sch 13521, Tafenil, Tecnoflut, Testotard, Goserelin, ICI-118630, Histrelin, Leuprolide, Leuprorelin, Radiation Therapy, Cancer Radiotherapy, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Relugolix, N-(4-(1-((2,6-Difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxyurea, Orgovyx, TAK 385, TAK-385, Triptorelin, 6-D-Tryptophan-LH-RH, 6-D-Tryptophanluteinizing Hormone-releasing Factor, AY-25650, CL-118,532, Detryptoreline
NRG Oncology, National Cancer Institute (NCI)
Prostate Adenocarcinoma
04/32
04/37
SMART, NCT03621644: Stereotactic MRI-guided On-table Adaptive Radiation Therapy () for Locally Advanced Pancreatic Cancer

Active, not recruiting
2
133
US, RoW
Stereotactic MRI-guided On-table Adaptive Radiation Therapy
Viewray Inc.
Pancreatic Cancer
08/22
01/27
NCT05846646: Study of PULSAR-ICI +/- IMSA101 in Patients with Oligometastatic NSCLC and RCC

Terminated
2
6
US
IMSA101, Immune checkpoint inhibitor, pembrolizumab, nivolumab, PULSAR
ImmuneSensor Therapeutics Inc.
Oligometastatic Disease
09/24
09/24
NCT05846659: Study of PULSAR-ICI +/- IMSA101 in Patients with Oligoprogressive Solid Tumor Malignancies

Terminated
2
16
US
IMSA101, Immune checkpoint inhibitor, pembrolizumab, nivolumab, PULSAR
ImmuneSensor Therapeutics Inc.
Oligoprogressive
11/24
11/24
DWI_RECT_MRGRT, NCT03961776: Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems

Recruiting
N/A
39
Europe, US
MRI-guided radiotherapy by on-board DWI sequences
Institut Paoli-Calmettes, University of California, Los Angeles
Rectal Adenocarcinoma
05/22
05/27
NCT01345851: Image-Guided Hypofractionated Radiation Therapy With Stereotactic Body Radiation Therapy Boost and Combination Chemotherapy in Treating Patients With Stage II-III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery

Active, not recruiting
N/A
29
US
hypofractionated radiation therapy, laboratory biomarker analysis, image-guided radiation therapy, carboplatin, Carboplat, CBDCA, JM-8, Paraplat, Paraplatin, paclitaxel, Anzatax, Asotax, TAX, Taxol, stereotactic body radiation therapy, SBRT, stereotactic radiation therapy, stereotactic radiotherapy
Jonsson Comprehensive Cancer Center, National Cancer Institute (NCI)
Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Large Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Squamous Cell Lung Cancer, Stage IIA Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
01/25
01/26
ARTIA-Prostate, NCT05804318: Daily Adaptive Radiation Therapy Using an Individualized Approach for Prostate Cancer

Recruiting
N/A
132
Europe, US
Daily adaptive SBRT with urethral sparing
Varian, a Siemens Healthineers Company
Prostate Cancer
03/25
03/30
Hernandez, Jackie
FMBRT, NCT04442724: Bladder Fiducial Markers and Multiparametric-MRI (mp-MRI) to Optimize Bladder Chemo-radiotherapy

Recruiting
N/A
60
US
Fiducial marker placement, Multiparametric MRI (mpMRI)
Cedars-Sinai Medical Center, National Cancer Institute (NCI)
Bladder Cancer, Urinary Bladder Neoplasm, Urologic Neoplasms, Neoplasms, Urinary Bladder Diseases
04/25
04/25
NCT05323253: A Clinical Study to Assess the Efficacy and Safety of Alpha DaRT224 for the Treatment of Patients With Recurrent Cutaneous Squamous Cell Carcinoma

Recruiting
N/A
86
Canada, US, RoW
DaRT seeds, DaRT
Alpha Tau Medical LTD.
Recurrent Squamous Cell Carcinoma
12/24
12/25
NCT05115760: Pea Protein Oral Nutrition Supplement for the Reduction of Gastrostomy Tube Placement Rate in Patients With Locally Advanced Head and Neck Cancer Undergoing Chemoradiation Therapy

Recruiting
N/A
60
US
Dietary Supplement, Dietary Supplements, Nutritional Supplement, Supplement, supplemental nutrition, Supplements, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
Jonsson Comprehensive Cancer Center, Kate Farms Inc
Locally Advanced Head and Neck Carcinoma
06/26
06/27

Download Options